- Home
- CAAP vs MLTX Comparison
CAAP vs MLTX Comparison
Compare CAAP & MLTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CAAP
- MLTX
- Stock Information
- Founded
- CAAP 1998
- MLTX 2021
- Country
- CAAP Luxembourg
- MLTX Switzerland
- Employees
- CAAP N/A
- MLTX N/A
- Industry
- CAAP Aerospace
- MLTX Biotechnology: Pharmaceutical Preparations
- Sector
- CAAP Consumer Discretionary
- MLTX Health Care
- Exchange
- CAAP Nasdaq
- MLTX Nasdaq
- Market Cap
- CAAP 3.3B
- MLTX 2.8B
- IPO Year
- CAAP 2018
- MLTX N/A
- Fundamental
- Price
- CAAP $19.90
- MLTX $53.09
- Analyst Decision
- CAAP Strong Buy
- MLTX Strong Buy
- Analyst Count
- CAAP 2
- MLTX 7
- Target Price
- CAAP $24.35
- MLTX $73.33
- AVG Volume (30 Days)
- CAAP 125.0K
- MLTX 455.8K
- Earning Date
- CAAP 08-20-2025
- MLTX 08-06-2025
- Dividend Yield
- CAAP N/A
- MLTX N/A
- EPS Growth
- CAAP N/A
- MLTX N/A
- EPS
- CAAP 1.05
- MLTX N/A
- Revenue
- CAAP $1,858,038,000.00
- MLTX N/A
- Revenue This Year
- CAAP $0.91
- MLTX $103.42
- Revenue Next Year
- CAAP $12.63
- MLTX N/A
- P/E Ratio
- CAAP $19.07
- MLTX N/A
- Revenue Growth
- CAAP 28.46
- MLTX N/A
- 52 Week Low
- CAAP $13.97
- MLTX $31.42
- 52 Week High
- CAAP $22.13
- MLTX $58.26
- Technical
- Relative Strength Index (RSI)
- CAAP 49.65
- MLTX 67.35
- Support Level
- CAAP $19.30
- MLTX $46.37
- Resistance Level
- CAAP $20.21
- MLTX $49.29
- Average True Range (ATR)
- CAAP 0.59
- MLTX 2.02
- MACD
- CAAP -0.02
- MLTX 0.44
- Stochastic Oscillator
- CAAP 43.56
- MLTX 81.64
About CAAP Corporacion America Airports SA
Corporacion America Airports SA acquires, develops, and operates airport concessions. Its operating segments are geographically divided into Argentina, Italy, Brazil, Uruguay, Ecuador, and Armenia. The company generates a majority of its revenue from the Argentina segment. The firm's revenue is categorized into Aeronautical Revenue, Non-Aeronautical Revenue, Commercial Revenue, Construction Service Revenue, and Other Revenue.
About MLTX MoonLake Immunotherapeutics
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients.